Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Articles online first > Minerva Cardioangiologica 2018 Feb 19

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA CARDIOANGIOLOGICA

Rivista sulle Malattie del Cuore e dei Vasi


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

Minerva Cardioangiologica 2018 Feb 19

DOI: 10.23736/S0026-4725.18.04640-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Antiplatelet therapy in STEMI undergoing primary PCI, when, which one and how long

Giorgio BARALIS, Roberta ROSSINI, Giuseppe MUSUMECI

USC Cardiologia, Dipartimento Emergenze e Aree Critiche, Ospedale Santa Croce e Carle, Cuneo, Italy


PDF  


Reperfusion therapy for patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) involves primary percutaneous coronary intervention (PPCI) and concomitant dual antiplatelet therapy (DAPT) with combination of a P2Y12 inhibitor and acetylsalicylic acid (ASA). Decision regarding DAPT can be challenging clinically in the modern era with the evolution of newer stents, more potent antiplatelet agents and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. This review outlines the currently available antiplatelet treatments, and their place within the therapeutic timeline of a patient presenting with STEMI.


KEY WORDS: Aspirin - Oral Antiplatelets - Coronary stent

inizio pagina

Publication History

Article first published online: February 19, 2018
Manuscript accepted: February 14, 2018
Manuscript received: February 10, 2018

Per citare questo articolo

Baralis G, Rossini R, Musumeci G. Antiplatelet therapy in STEMI undergoing primary PCI, when, which one and how long. Minerva Cardioangiol 2018 Feb 19. DOI: 10.23736/S0026-4725.18.04640-6

Corresponding author e-mail

giuseppe.musumeci@gmail.com